Pfizer stock gains as BMO reiterates Outperform rating amid Trump deal
PositiveFinancial Markets

Pfizer's stock has seen a notable increase following BMO's decision to reiterate its Outperform rating, particularly in light of a recent deal involving former President Trump. This development is significant as it reflects investor confidence in Pfizer's future performance and the potential impact of political events on the pharmaceutical industry.
— Curated by the World Pulse Now AI Editorial System